Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Pertusati, Fabrizio; Serpi, Michaela; McGuigan, Christopher (2011)
Publisher: Nucleus Global
Languages: English
Types: Article
Subjects: RM
Considerable attention has been focused on the development of phosphonate-containing drugs for application in many therapeutic areas. However, phosphonate diacids are deprotonated at physiological pH and thus phosphonate-containing drugs are not ideal for oral administration, an extremely desirable requisite for the treatment of chronic diseases. To overcome this limitation several prodrug structures of biologically active phosphonate analogues have been developed. The rationale behind the design of such agents is to achieve temporary blockade of the free phosphonic functional group until their systemic absorption and delivery, allowing the release of the active drug only once at the target. In this paper, an overview of acyclic and cyclic nucleoside phosphonate prodrugs, designed as antiviral agents, is presented.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. De Clercq E & Neyts J. Antiviral agents acting as DNA or RNA chain terminators. Handb. Exp. Pharmacol. 2009:53-84.
    • 2. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochemical Pharmacology 2011; 82:99-109.
    • 3. De Clercq E & Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4:928-940.
    • 4. Holý A. Phosphonomethoxyalkyl analogs of nucleotides. Curr. Pharm. Des. 2003 9:2567- 2592.
    • 5. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J & Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323:464-467.
    • 6. De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hockova D & Holý A. Antiviral Potential of a New Generation of Acyclic Nucleoside Phosphonates, the 6-[2-(Phosphonomethoxy)Alkoxy]-2,4-Diaminopyrimidines. NNNA 2005; 24:331 - 341.
    • 7. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I & Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987; 8:261-272.
    • 8. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. Antiviral Res. 2007; 75:1-13.
    • 9. De Clercq E & Neyts J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. in Med. Virol. 2004; 14:289-300.
    • 10. Dal Pozzo F, Andrei G, Holy A, Van Den Oord J, Scagliarini A, De Clercq E & Snoeck R. Activities of Acyclic Nucleoside Phosphonates against Orf Virus in Human and Ovine Cell Monolayers and Organotypic Ovine Raft Cultures. Antimicrob. Agents Chemother. 2005; 49:4843-4852. 1315923.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article